Drugs / Tilesizumab
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05690945 Comparator | Feb 2023 → Jun 2029 expected | lung cancer | Qilu Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tilesizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05690945 ↗ |
| Route | Intravenous | “Tilesizumab will be administered by IV infusion” NCT05690945 ↗ |